1 Department of Radiology, New York University School of Medicine, 221 Lexington Ave, New York, NY 10016.
AJR Am J Roentgenol. 2018 Feb;210(2):246-255. doi: 10.2214/AJR.17.18778. Epub 2017 Oct 18.
Ductal carcinoma in situ (DCIS) is a noninvasive malignant breast disease traditionally described as a precursor lesion to invasive breast cancer. With screening mammography, DCIS now accounts for approximately 20% of newly diagnosed cancer cases. DCIS is not well understood because of its heterogeneous nature.
Studies have aimed to assess prognostic factors to characterize its risk of invasive potential; however, there still remains a lack of uniformity in workup and treatment. We summarize current knowledge of DCIS and the ongoing controversies.
导管原位癌（DCIS）是一种非浸润性恶性乳腺疾病，传统上被描述为浸润性乳腺癌的前体病变。随着筛查性乳房 X 光检查的普及，DCIS 现在约占新诊断癌症病例的 20%。由于其异质性，DCIS 尚未得到很好的理解。
研究旨在评估预后因素以描述其浸润潜力的风险；然而，在检查和治疗方面仍然缺乏一致性。我们总结了 DCIS 的现有知识和正在讨论的争议。
